Executive Summary
HHS awarded $548M in contracts signaling robust demand for biomedical R&D and CDC infrastructure, with Leidos Biomedical (Leidos Holdings, LDOS) securing $327M obligation (potential $776M) for NCI tasks and HCBeck nearing completion of $221M CDC construction. Both full/open competition awards highlight reliable revenue for non-small businesses amid FY26-FY27 health priorities. Investors should prioritize LDOS for multi-year upside while monitoring construction finalization risks.
Tracking the trend? Catch up on the prior All HHS Contracts digest from February 06, 2026.
Investment Signals(2)
- HHS R&D revenue surge for Leidos(HIGH)▲
Leidos Biomedical's $327M obligation (potential $776M total) under cost-plus-fixed-fee adds reliable FY26-FY27 revenue from NCI operational tasks.
- CDC infra spend nears completion(HIGH)▲
$221M firm-fixed-price contract 96% outlayed ($212M/$221M), securing HCBeck revenue through 2025.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
Leidos options unexercised ($449M potential) and low initial outlay ($24M vs $327M obligation); HCBeck $10M remainder vulnerable to delays/cost overruns.
Opportunities(2)
- ◆
Leidos potential expansion to $776M via options and 2027 extension.
- ◆
CDC campus follow-ons post-Phase II completion.
Sector Themes(1)
- ◆
NIH/CDC prioritize operational R&D ($327M) and facilities ($221M) via full/open awards to large firms.
Watch List(2)
- 👁
{"entity"=>"Leidos Holdings (LDOS)", "reason"=>"$776M potential dwarfs $548M period total; parent captures R&D upside.", "trigger"=>"Option exercises >$449M"}
- 👁
{"entity"=>"HCBeck, Ltd.", "reason"=>"96% complete $221M CDC project signals follow-on potential.", "trigger"=>"Full $221M outlay by Oct 2025"}
Get daily alerts with 2 investment signals, 1 risk alerts, 2 opportunities and full AI analysis of all 2 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC